Skip to main content

Emicizumab Activity

CPT 80299
Synonyms
  • Hemlibra

Test Details

Methodology

One stage clot detection

Result Turnaround Time

7 - 10 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Use

This assay is intended for the evaluation of plasma emicizumab levels (µg/mL) in patients receiving emicizumab therapy.

Limitations

Patients receiving factor VIII replacement therapy in addition to emicizumab may show falsely elevated results, as will patients with significant native factor VIII levels (greater than 25% native factor VIII activity). If factor VIII inhibitor levels are required while the patient is on emicizumab, this can be ordered by using Factor VIII Chromogenic Bethesda Profile, for Patients on Emicizumab [504722].

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Specimen Requirements

Specimen

Citrated plasma, frozen

Volume

1 mL

Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)

Container

Light blue-top (3.2% sodium citrate) collection tube

Collection Instructions

Separate plasma from cells by centrifugation. Centrifuge separated plasma to yield platelet-poor plasma. Transfer plasma to a plastic transport tube before freezing.

Storage Instructions

Freeze. Stable at room temperature for 6 hours, and for 3 additional freeze/thaw Instructions cycles.

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
505715 Emicizumab Activity 505716 Emicizumab Activity ug/mL 99614-0
Order Code505715
Order Code NameEmicizumab Activity
Order Loinc
Result Code505716
Result Code NameEmicizumab Activity
UofMug/mL
Result LOINC99614-0